Oral intake of curcumin markedly activated CYP 3A4: In vivo and ex-vivo studies

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Hsieh, Yow Wen ^a,b   Huang, Ching Ya ^a,b   Yang, Shih Ying ^a   Peng, Yu Hsuan ^a   Yu, Chung Ping ^a   Chao, Pei Dawn Lee ^a   Hou, Yu Chi ^a,b  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYTOCHROME P450 3A; EVEROLIMUS; MULTIDRUG RESISTANCE PROTEIN; RAPAMYCIN;

ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BIOSYNTHESIS; DRUG INTERACTION; GENETICS; HUMAN; NEOPLASMS; ORAL DRUG ADMINISTRATION; RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CURCUMIN; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; NEOPLASMS; P-GLYCOPROTEIN; RATS; SIROLIMUS;

EID: 84934321954     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06587     Document Type: Article

References (35)

1. Chihiro, T., Natsuki, N., Fumiyuki, H. & Katsuko, K. Comparison of anti-inflammatory activities of six Curcuma Rhizomes: a possible curcuminoid-independent pathway mediated by Curcuma phaeocaulis extract. Evid Based Complement Alternat Med 3, 255-260 (2006).
2. Nakmareong, S. et al. Antioxidant and vascular protective effects of curcumin and tetrahydrocurcumin in rats with l-NAME-induced hypertension. Naunyn Schmiedebergs Arch Pharmacol 383, 519-529 (2011).
3. Odot, J. et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111, 381-387 (2004).
4. Garcia-Alloza, M., Borrelli, L. A., Rozkalne, A., Hyman, B. T. & Bacskai, B. J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102, 1095-1104 (2007).
5. Li, J. et al. A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomed Chromatog 23, 1201-1207 (2009).
6. Vareed, S. K. et al. Pharmacokinetics of curcumin conjugate metabolites in healthy subjects. Cancer Epidemiol Biomarkers Prev 17, 1411-1417 (2008).
7. Liu, Z. et al. Enhancement of curcumin oral absorption and pharmacolinetics of curcuminoids and curcurmin metabolites in mice. Cancer Chemother Pharmacol 69, 679-689 (2012).
8. Gurk-Turner, C., Manitpisitkul, W. & Cooper, M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 94, 659-668 (2012).
9. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366, 520-529 (2012).
10. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449-456 (2008).
11. Mabasa, V. H. & Ensom, M. H. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit 27, 666-676 (2005).
12. Zaza, G. et al. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013, 403280 (2013).
13. Barroso-Sousa, R., Santana, I. A., Testa, L., de Melo Gagliato, D. & Mano, M. S. Biological therapies in breast cancer: common toxicities and management strategies. Breast 22, 1009-1018 (2013).
14. Junpaparp, P., Sharma, B., Samiappan, A., Rhee, J. H. & Young, K. R. Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage. Ann Am Thorac Soc 10, 727-729 (2013).
15. Kirchner, G. I., Meier-Wiedenbach, I. & Manns, M. P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43, 83-95 (2004).
16. Bohra, R. et al. Everolimus and sirolimus in combination with cyclosporine have different effects on renal metabolism in the rat. PLoS One 7, e48063 (2012).
17. Monchaud, C. & Marquet, P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II. Clin Pharmacokinet 48, 489-516 (2009).
18. Anuchapreeda, S., Leechanachai, P., Smith, M. M., Ambudkar, S. V. & Limtrakul, P. N. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64, 573-582 (2002).
19. Lu, W. D., Qin, Y., Yang, C. & Li, L. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo. Clinics 68, 694-701 (2013).
20. Okura, T., Ibe, M., Umegaki, K., Shinozuka, K. & Yamada, S. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 33, 255-259 (2010).
21. Appiah-Opong, R., Commandeur, J. N., van Vugt-Lussenburg, B. & Vermeulen, N. P. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology 235, 83-91 (2007).
22. Bamba, Y., Yun, Y.S., Kunugi, A. & Inoue, H. Compounds isolated from Curcuma aromatica Salisb. inhibit human P450 enzymes. J Nat Med 65, 583-587 (2011).
23. Hou, X. L. et al. Curdione plays an important role in the inhibitory effect of Curcuma aromatica on CYP3A4 in Caco-2 Cells. Evid Based Complement Alternat Med 2011, 913898 (2011).
24. Zhou, S. F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9, 310-322 (2008).
25. Thakrar, B. T., Grundschober, S. B. & Doessegger, L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 64, 489-495 (2007).
26. Simard, C. et al. Study of the drug-drug interaction between simvastatin and cisapride in man. Eur J Clin Pharmacol 57, 229-234 (2001).
27. Fujita, K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20, 195-217 (2004).
28. Hsu, P. W. et al. Potential risk of mulberry-drug interaction: modulation on P-glycoprotein and cytochrome P450 3A. J Agric Food Chem 61, 4464-4469 (2013).
29. Yang, S. Y., and Tsai, S. Y., Hou, Y. C. & Chao, P. D. L. Inductive modulation on P-glycoprotein and cytochrome 3A by resveratrol, a constituent of grapes. Food Chem 133, 683-688 (2012).
30. Yu, C. P. et al. Potential modulation on P-glycoprotein and CYP3A by soymilk and miso: in vivo and ex-vivo studies. Food Chem 149, 25-30 (2014).
31. Dasgupta, A., Davis, B. & Chow, L. Evaluation of QMS Everolimus assay using Hitachi 917analyzer: comparison with liquid chromatography/mass spectrometry. Ther Drug Monit 33, 149-154 (2011).
32. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63 (1983).
33. Jia, J. X. & Wasan, K. M. Effects of monoglycerides on rhodamine 123 accumulation, estradiol 17 beta-D-glucuronide bidirectional transport and MRP2 protein expression within Caco-2 cells. J Pharm Pharm Sci 11, 45-62 (2008).
34. Lin, S. P., and Chao, P. D., Tsai, S. Y., Wang, M. J. & Hou, Y. C. Citrus grandis peel increases the bioavailability of cyclosporine and tacrolimus, two important immunosuppressants, in rats. J Med Food 14, 1463-1468 (2011).
35. Yu, C. P. et al. Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric Food Chem 59, 4644-4648 (2011).